NEO100 Brain Cancer Breakthrough
NeOnc's NEO100 Brain Cancer Study Exceeds Benchmark by 2.5x in Phase 2a Results
NeOnc Technologies Holdings (NASDAQ: NTHI) has reported a major milestone in brain cancer treatment. Its intranasal drug NEO100 showed a 48.9% six-month progression-free survival rate in a Phase 2a trial — nearly 2.5 times the 20% historical benchmark, according to Woodstock Sentinel Review.
The result was statistically significant. The study enrolled 24 patients with advanced recurrent Grade III or Grade IV glioma — aggressive brain tumors that had already returned after standard radiation and chemotherapy. The drug is administered through the nose four times daily and can be taken at home.
How NEO100 Nearly Tripled the Survival Benchmark
Progression-free survival measures how long a patient lives without their tumor growing. The historical benchmark for this patient group sits at just 20% at six months. NEO100 hit 48.9%, according to The Whig. That gap — nearly 2.5 times the benchmark — was large enough to be statistically significant, meaning it is unlikely to be a result of chance.
The trial focused specifically on patients with recurrent IDH1-mutant high-grade glioma, as Daily Herald Tribune reported. IDH1 mutations are a specific genetic marker found in certain brain tumors. These patients had already exhausted standard treatments, making the results especially notable.
A Nose-Delivered Drug Patients Can Take at Home
NEO100 is delivered intranasally — through the nose. Patients take it four times a day. Crucially, they can do this at home, without hospital visits, according to Recorder. This sets it apart from many cancer treatments that require infusions or clinic trips.
The nose-to-brain delivery route is intentional. It allows the drug to bypass the blood-brain barrier — the body's natural shield that blocks most medications from reaching the brain. This approach could be a key reason the drug showed strong activity against these hard-to-treat tumors.
NeOnc Now Eyes FDA Meeting and Larger Trial
NeOnc plans to meet with the FDA to discuss next steps. The goal is to design a larger registrational study — the kind of trial that can support full drug approval, according to Mitchell Advocate. A successful registrational study would put NEO100 on a path toward becoming an approved treatment.
Phase 2a trials are small and early-stage. They test whether a drug shows enough promise to keep going. Clearing the 20% benchmark so decisively gives NeOnc a strong case to make to regulators, though larger trials will still need to confirm the results.
Investors Take Notice as NTHI Stock Draws Attention
The Phase 2a results have drawn fresh attention from investors, according to Stratford Beacon Herald. Shares of NeOnc trade on NASDAQ under the ticker NTHI. The strong trial data has prompted market watchers to begin evaluating the commercial significance of the NEO100 results.
Recurrent high-grade glioma is one of the hardest cancers to treat. There are very few approved options after standard therapy fails. A drug that nearly triples progression-free survival in this group — if confirmed in larger studies — could represent a significant unmet medical need being addressed, noted Fairview Post.
Sentiment
NeutralPublishers
12
Articles
12
Reach
12
